1	Genetically	_	_	RB	_	_	_	_	_
2	altered	_	_	VBN	_	_	_	_	_
3	mice	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	"	_	_	``	_	_	_	_	_
6	superathletes	_	_	NNS	_	_	_	_	_
7	"	_	_	''	_	_	_	_	_


1	Friday	_	_	NNP	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	November	_	_	NNP	_	_	_	_	_
4	2	_	_	CD	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	2007	_	_	CD	_	_	_	_	_


1	Researchers	_	_	NNS	_	_	_	_	_
2	at	_	_	IN	_	_	_	_	_
3	Case	_	_	NNP	_	_	_	_	_
4	Western	_	_	NNP	_	_	_	_	_
5	University	_	_	NNP	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	Cleveland	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	Ohio	_	_	NNP	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	announced	_	_	VBN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	creation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	transgenic	_	_	JJ	_	_	_	_	_
16	mice	_	_	NNS	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	substantially	_	_	RB	_	_	_	_	_
19	improved	_	_	VBN	_	_	_	_	_
20	athletic	_	_	JJ	_	_	_	_	_
21	endurance	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	live	_	_	VBP	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	breed	_	_	VBP	_	_	_	_	_
27	longer	_	_	RBR	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	are	_	_	VBP	_	_	_	_	_
30	more	_	_	RBR	_	_	_	_	_
31	aggressive	_	_	JJ	_	_	_	_	_
32	than	_	_	IN	_	_	_	_	_
33	genetically	_	_	RB	_	_	_	_	_
34	unmodified	_	_	JJ	_	_	_	_	_
35	siblings	_	_	NNS	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	are	_	_	VBP	_	_	_	_	_
39	leaner	_	_	JJR	_	_	_	_	_
40	despite	_	_	IN	_	_	_	_	_
41	consuming	_	_	VBG	_	_	_	_	_
42	60	_	_	CD	_	_	_	_	_
43	%	_	_	NN	_	_	_	_	_
44	more	_	_	JJR	_	_	_	_	_
45	food	_	_	NN	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	mice	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	dubbed	_	_	VBN	_	_	_	_	_
6	"	_	_	``	_	_	_	_	_
7	mighty	_	_	JJ	_	_	_	_	_
8	mice	_	_	NNS	_	_	_	_	_
9	"	_	_	''	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	"	_	_	``	_	_	_	_	_
12	supermice	_	_	NN	_	_	_	_	_
13	"	_	_	''	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	popular	_	_	JJ	_	_	_	_	_
17	press	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	have	_	_	VBP	_	_	_	_	_
20	been	_	_	VBN	_	_	_	_	_
21	compared	_	_	VBN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	cyclist	_	_	NN	_	_	_	_	_
24	Lance	_	_	NNP	_	_	_	_	_
25	Armstrong	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	changes	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	created	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	adding	_	_	VBG	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	extra	_	_	JJ	_	_	_	_	_
9	copy	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	single	_	_	JJ	_	_	_	_	_
13	gene	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	PEPCK-C	_	_	NNP	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	gene	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	already	_	_	RB	_	_	_	_	_
5	present	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	mouse	_	_	NN	_	_	_	_	_
9	genome	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	but	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	modified	_	_	VBN	_	_	_	_	_
14	gene	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	designed	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	strongly	_	_	RB	_	_	_	_	_
20	active	_	_	JJ	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	transcribed	_	_	VBN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	skeletal	_	_	JJ	_	_	_	_	_
26	muscle	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	The	_	_	DT	_	_	_	_	_
30	natural	_	_	JJ	_	_	_	_	_
31	copy	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	gene	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	most	_	_	RBS	_	_	_	_	_
37	active	_	_	JJ	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	liver	_	_	NN	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	continues	_	_	VBZ	_	_	_	_	_
43	to	_	_	TO	_	_	_	_	_
44	function	_	_	VB	_	_	_	_	_
45	normally	_	_	RB	_	_	_	_	_
46	)	_	_	-RRB-	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	gene	_	_	NN	_	_	_	_	_
3	mediates	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	crucial	_	_	JJ	_	_	_	_	_
6	rate	_	_	NN	_	_	_	_	_
7	controlling	_	_	VBG	_	_	_	_	_
8	step	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	gluconeogenesis	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	glyceroneogenesis	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	its	_	_	PRP$	_	_	_	_	_
16	activity	_	_	NN	_	_	_	_	_
17	helps	_	_	VBZ	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	allow	_	_	VB	_	_	_	_	_
20	energy	_	_	NN	_	_	_	_	_
21	production	_	_	NN	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	mitochondrial	_	_	JJ	_	_	_	_	_
25	citric	_	_	JJ	_	_	_	_	_
26	acid	_	_	NN	_	_	_	_	_
27	cycle	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	transgenics	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	more	_	_	JJR	_	_	_	_	_
6	energy	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	available	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	muscle	_	_	VB	_	_	_	_	_
11	through	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	burning	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	fatty	_	_	NN	_	_	_	_	_
16	acids	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	much	_	_	RB	_	_	_	_	_
20	less	_	_	JJR	_	_	_	_	_
21	production	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	lactate	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	chemical	_	_	NN	_	_	_	_	_
27	that	_	_	WDT	_	_	_	_	_
28	leads	_	_	VBZ	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	sore	_	_	JJ	_	_	_	_	_
31	muscles	_	_	NNS	_	_	_	_	_
32	when	_	_	WRB	_	_	_	_	_
33	one	_	_	CD	_	_	_	_	_
34	exercises	_	_	VBZ	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	as	_	_	RB	_	_	_	_	_
5	major	_	_	JJ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	change	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	mouse	_	_	NN	_	_	_	_	_
11	genome	_	_	NN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	might	_	_	MD	_	_	_	_	_
15	seem	_	_	VB	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	layperson	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	PEPCK-C	_	_	NNP	_	_	_	_	_
3	gene	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	already	_	_	RB	_	_	_	_	_
6	present	_	_	JJ	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	mouse	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	variety	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	natural	_	_	JJ	_	_	_	_	_
15	mutations	_	_	NNS	_	_	_	_	_
16	could	_	_	MD	_	_	_	_	_
17	likely	_	_	RB	_	_	_	_	_
18	cause	_	_	VB	_	_	_	_	_
19	similar	_	_	JJ	_	_	_	_	_
20	results	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	appears	_	_	VBZ	_	_	_	_	_
4	today	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	Journal	_	_	NNP	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	Biological	_	_	NNP	_	_	_	_	_
10	Chemistry	_	_	NNP	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	paper	_	_	NN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	lead	_	_	JJ	_	_	_	_	_
16	author	_	_	NN	_	_	_	_	_
17	Parvin	_	_	NNP	_	_	_	_	_
18	Hakimi	_	_	NNP	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	laboratory	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	Richard	_	_	NNP	_	_	_	_	_
24	W.	_	_	NNP	_	_	_	_	_
25	Hanson	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	altered	_	_	VBN	_	_	_	_	_
3	mice	_	_	NNS	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	run	_	_	VB	_	_	_	_	_
6	at	_	_	IN	_	_	_	_	_
7	20	_	_	CD	_	_	_	_	_
8	meters	_	_	NNS	_	_	_	_	_
9	per	_	_	IN	_	_	_	_	_
10	minute	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	0.75	_	_	CD	_	_	_	_	_
13	miles	_	_	NNS	_	_	_	_	_
14	per	_	_	IN	_	_	_	_	_
15	hour	_	_	NN	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	1.2	_	_	CD	_	_	_	_	_
18	kilometers	_	_	NNS	_	_	_	_	_
19	per	_	_	IN	_	_	_	_	_
20	hour	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	up	_	_	IN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	six	_	_	CD	_	_	_	_	_
26	kilometers	_	_	NNS	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	nearly	_	_	RB	_	_	_	_	_
29	four	_	_	CD	_	_	_	_	_
30	miles	_	_	NNS	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	without	_	_	IN	_	_	_	_	_
33	stopping	_	_	VBG	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	average	_	_	JJ	_	_	_	_	_
3	treadmill	_	_	NN	_	_	_	_	_
4	time	_	_	NN	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	strenuous	_	_	JJ	_	_	_	_	_
7	exercise	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	25-degree	_	_	JJ	_	_	_	_	_
11	incline	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	31.9	_	_	CD	_	_	_	_	_
14	minutes	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	well	_	_	RB	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	excess	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	19	_	_	CD	_	_	_	_	_
22	minute	_	_	NN	_	_	_	_	_
23	average	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	unmodified	_	_	JJ	_	_	_	_	_
26	mice	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Females	_	_	NNS	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	breed	_	_	VB	_	_	_	_	_
4	at	_	_	IN	_	_	_	_	_
5	two	_	_	CD	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	half	_	_	CD	_	_	_	_	_
9	years	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	age	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	whereas	_	_	IN	_	_	_	_	_
14	most	_	_	JJS	_	_	_	_	_
15	female	_	_	JJ	_	_	_	_	_
16	mice	_	_	NNS	_	_	_	_	_
17	cannot	_	_	MD	_	_	_	_	_
18	breed	_	_	VB	_	_	_	_	_
19	after	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	first	_	_	JJ	_	_	_	_	_
22	year	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	colony	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	500	_	_	CD	_	_	_	_	_
5	mice	_	_	NNS	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	bred	_	_	VBN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	starting	_	_	VBG	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	six	_	_	CD	_	_	_	_	_
13	independent	_	_	JJ	_	_	_	_	_
14	germline	_	_	NN	_	_	_	_	_
15	transformations	_	_	NNS	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	"	_	_	``	_	_	_	_	_
18	founder	_	_	NN	_	_	_	_	_
19	"	_	_	''	_	_	_	_	_
20	mice	_	_	NNS	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	level	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	PEPCK-C	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	muscle	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	9	_	_	CD	_	_	_	_	_
9	units	_	_	NNS	_	_	_	_	_
10	per	_	_	IN	_	_	_	_	_
11	gram	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	muscle	_	_	NN	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	opposed	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	only	_	_	RB	_	_	_	_	_
18	0.08	_	_	CD	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	normal	_	_	JJ	_	_	_	_	_
21	mice	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Levels	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	triglycerides	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	number	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	mitochondria	_	_	NN	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	increased	_	_	VBN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Hanson	_	_	NNP	_	_	_	_	_
2	said	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	he	_	_	PRP	_	_	_	_	_
5	did	_	_	VBD	_	_	_	_	_
6	not	_	_	RB	_	_	_	_	_
7	expect	_	_	VB	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	results	_	_	NNS	_	_	_	_	_
11	would	_	_	MD	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	applicable	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	humans	_	_	NNS	_	_	_	_	_
16	due	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	both	_	_	CC	_	_	_	_	_
19	practical	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	ethical	_	_	JJ	_	_	_	_	_
22	considerations	_	_	NNS	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	addition	_	_	NN	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	fact	_	_	NN	_	_	_	_	_
28	that	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	genes	_	_	NNS	_	_	_	_	_
31	might	_	_	MD	_	_	_	_	_
32	not	_	_	RB	_	_	_	_	_
33	function	_	_	VB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	same	_	_	JJ	_	_	_	_	_
36	way	_	_	NN	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	humans	_	_	NNS	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	first	_	_	JJ	_	_	_	_	_
6	time	_	_	NN	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	press	_	_	NN	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	dubbed	_	_	VBN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	genetically	_	_	RB	_	_	_	_	_
14	modified	_	_	VBN	_	_	_	_	_
15	mouse	_	_	NN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	"	_	_	``	_	_	_	_	_
18	mighty	_	_	JJ	_	_	_	_	_
19	mouse	_	_	NN	_	_	_	_	_
20	"	_	_	''	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Earlier	_	_	RBR	_	_	_	_	_
2	scientists	_	_	NNS	_	_	_	_	_
3	at	_	_	IN	_	_	_	_	_
4	John	_	_	NNP	_	_	_	_	_
5	Hopkins	_	_	NNP	_	_	_	_	_


1	University	_	_	NNP	_	_	_	_	_
2	announced	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	they	_	_	PRP	_	_	_	_	_
5	had	_	_	VBD	_	_	_	_	_
6	made	_	_	VBN	_	_	_	_	_
7	mice	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	massively	_	_	RB	_	_	_	_	_
10	increased	_	_	VBN	_	_	_	_	_
11	muscle	_	_	NN	_	_	_	_	_
12	mass	_	_	NN	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	were	_	_	VBD	_	_	_	_	_
15	larger	_	_	JJR	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	stronger	_	_	JJR	_	_	_	_	_
18	than	_	_	IN	_	_	_	_	_
19	their	_	_	PRP$	_	_	_	_	_
20	normal	_	_	JJ	_	_	_	_	_
21	cousins	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	alterations	_	_	NNS	_	_	_	_	_
3	increased	_	_	VBD	_	_	_	_	_
4	strength	_	_	NN	_	_	_	_	_
5	rather	_	_	RB	_	_	_	_	_
6	than	_	_	IN	_	_	_	_	_
7	endurance	_	_	NN	_	_	_	_	_
8	through	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	genetic	_	_	JJ	_	_	_	_	_
11	modification	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	myostatin	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	follistatin	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	injection	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	soluble	_	_	JJ	_	_	_	_	_
23	form	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	ACVR2B	_	_	NN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	block	_	_	VB	_	_	_	_	_
28	myostatin	_	_	NN	_	_	_	_	_
29	activity	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	normal	_	_	JJ	_	_	_	_	_
32	mice	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_

